Ex-As­traZeneca ex­ec Lisa An­son to lead do-over at Redx; Ad­vax­is shakes up C-suite

Lisa An­son

Redx $REDX has en­list­ed es­teemed British ex­ec Lisa An­son to lead the com­pa­ny’s do-over as its CEO. Hav­ing held man­age­ment roles at As­traZeneca for 20 years — serv­ing as As­traZeneca UK’s pres­i­dent for the last six — An­son, who’s al­so the pres­i­dent of the As­so­ci­a­tion of the British Phar­ma­ceu­ti­cal In­dus­try, in­spires con­fi­dence about turn­ing things around for the bat­tered biotech. If the hopes are high, so are the stakes. Redx saw its shares sus­pend­ed al­most a year ago af­ter the city of Liv­er­pool said it went delin­quent on a £2 mil­lion loan, and was hit by a safe­ty cri­sis just last month that forced it to halt a PhI/II tri­al. An­son, how­ev­er, is up­beat about the work cut out for her: “The team have im­pressed me and the com­pa­ny now has a clear fo­cus on some very ex­cit­ing ar­eas of sci­ence in both fi­bro­sis and can­cer where there are a num­ber of on­go­ing pro­grams.” When she comes on the job on June 1, ex­ec­u­tive chair­man Iain Ross will re­vert to a non-ex­ec­u­tive po­si­tion.

Ad­vax­is$ADXS C-suite is buzzing with ac­tiv­i­ty as it names two new ex­ecs while part­ing ways with an­oth­er. Ken­neth Berlin, a J&J vet jump­ing from the helm of di­ag­nos­tics com­pa­ny Roset­ta Ge­nomics, is tak­ing over the roles of pres­i­dent and CEO from in­ter­im chief ex­ec­u­tive An­tho­ny Lom­bar­do. He will be as­sist­ed on the clin­i­cal side by new CMO An­dres Gutier­rez, who’s tak­ing charge of all de­vel­op­ment and reg­u­la­to­ry ac­tiv­i­ties for Ad­vax­is’ Lis­te­ria mono­cy­to­genes-based anti­gen de­liv­ery plat­form. Bring­ing ex­pe­ri­ence with a slate of can­cer im­munother­a­pies at On­colyt­ics Biotech and Sel­l­as, where he held the same role, Gutier­rez in­her­its a lead drug — ax­al­imo­gene filolis­bac — that’s well in­to Phase III de­vel­op­ment but haunt­ed by an FDA clin­i­cal hold on a PhI/II tri­al eval­u­at­ing a com­bo treat­ment with the drug and As­traZeneca’s Imfinzi, is­sued weeks ago. Con­cur­rent­ly, CFO Sara Bon­stein is leav­ing the Prince­ton, NJ-based com­pa­ny for an­oth­er op­por­tu­ni­ty. While she is leav­ing al­most im­me­di­ate­ly, Lom­bar­do will stay for a while for the tran­si­tion.

→ Al­most two decades af­ter co-found­ing Pro­bio­drug, Kon­rad Glund has de­cid­ed it’s time to pass on the reins — and he’s se­lect­ed a fel­low en­tre­pre­neur-ex­ec­u­tive. Ul­rich Dauer had worked 14 years as chief ex­ec­u­tive of 4SC, a can­cer drug de­vel­op­er he helped start, be­fore tak­ing more re­cent stints at Ven­ta­le­on and Ome­icos Ther­a­peu­tics. As CEO, Dauer will work close­ly with long­time chief de­vel­op­ment of­fi­cer Inge Lues to push Pro­bio­drug’s Alzheimer’s dis­ease can­di­date in­to Phase IIb stud­ies, tak­ing ad­van­tage of FDA’s new guide­lines for the no­to­ri­ous­ly hard to treat dis­ease. The hope is that the re­sults would be good enough to war­rant con­di­tion­al ap­proval of the drug, dubbed PQ912. Al­so step­ping down from the front line: CFO Hen­drik Liebers, who will be­come an ad­vis­er along­side Glund.

→ With ear­ly-stage clin­i­cal tri­als un­der­way at gas­troin­testi­nal spe­cial­ist Or­phoMed, Gary Phillips has been tapped as CEO so that founder Nikhilesh Singh can tran­si­tion to a new­ly cre­at­ed CSO po­si­tion. The ap­point­ment brings Phillips to San Fran­cis­co af­ter four years in Lon­don, where he worked as EVP and chief strat­e­gy of­fi­cer for Mallinck­rodt Phar­ma. That was af­ter al­most 20 years of mov­ing back and forth across the At­lantic for a se­ries of jobs at com­pa­nies like Bausch & Lomb, No­var­tis and Mer­ck KGaA. While he steers strat­e­gy and op­er­a­tions, Singh will de­vote his time to a pipeline of dimer ther­a­peu­tics.

→ Af­ter 7 years as head of Sanofi R&D, for­mer NIH chief Elias Zer­houni is step­ping down and hand­ing the job to John Reed, who spent the last 5 years run­ning Roche’s pRED re­search group based in Basel. Reed, like Zer­houni, will have of­fices in Cam­bridge, MA. The change at the top of the Paris-based phar­ma gi­ant’s re­search arm marks the lat­est in a se­ries of switch-ups in the world’s biggest phar­ma R&D or­ga­ni­za­tions. Both Reed and Zer­houni are known as in­flu­en­tial sci­en­tists with a keen un­der­stand­ing of trans­la­tion­al re­search. But they’ve nev­er made the leap to be­come known for mas­ter­ing de­vel­op­ment on their own. Reed is join­ing Sanofi April 30, two months be­fore Zer­houni leaves Sanofi.

→ As Dermtreat makes its sec­ond home in San Diego, it has tapped an Amer­i­can CEO, Nis­han de Sil­va, to ad­vance late-stage clin­i­cal tri­als for its mu­cos­al patch. Riv­elin, de­vel­oped by founder Jens Hansen and backed by Sofinno­va, treats the au­toim­mune dis­ease oral lichen planus by di­rect­ly de­liv­er­ing a drug to mouth sur­faces. In his new role as pres­i­dent of R&D, Hansen will con­tin­ue to over­see­ing the com­pa­ny’s Den­mark-based op­er­a­tions. With a back­ground in health­care con­sult­ing and pri­vate eq­ui­ty in­vest­ing, de Sil­va joins Dermtreat from the pres­i­dent and COO seat at Po­sei­da Ther­a­peu­tics. His top march­ing or­der is to chart a com­mer­cial path for Riv­elin, which is set for PhI­Ib tri­als in mid-2018 us­ing the drug clo­be­ta­sol.

→ Cana­da’s Scythi­an Bio­sciences has brought in Eu­ro­pean med­ical cannabis ex­pert Rob Reid to re­place CEO Jonathan Gilbert, who’s now tasked with a more fo­cused role man­ag­ing the com­pa­ny’s part­ner­ship with the Uni­ver­si­ty of Mi­a­mi. Es­tab­lished in 2016, the part­ner­ship seeks to eval­u­ate Scythi­an’s cannabi­noid-based pill in con­cus­sion in­juries, with both ro­dent and hu­man stud­ies planned.

→ Two-time biotech CEO Matthias Schroff is now the chief op­er­at­ing of­fi­cer at Ex­i­cure, where he gets to flex all his im­muno-on­col­o­gy, TLR9 bi­ol­o­gy and RNAi mus­cles. The Ger­man ex­ec ar­rives at a time the Chica­go-based biotech is wrap­ping up Phase I stud­ies for its lead sol­id tu­mor drug and an­oth­er pso­ri­a­sis treat­ment. He is ex­pect­ed to put the deep clin­i­cal ex­pe­ri­ence he honed dur­ing his runs at Vax­imm and Molo­gen to use, help­ing break new grounds with the spher­i­cal nu­cle­ic acid de­liv­ery tech­nol­o­gy de­vel­oped in part by CEO David Giljo­hann.

Kei­th Katkin has as­sem­bled a star-stud­ded team in prepa­ra­tion for piv­otal tri­als and even­tu­al com­mer­cial­iza­tion at Urovant Sci­ences. Three of the five new hires share roots in Al­ler­gan: CMO Cor­nelia Haag-Molken­teller led clin­i­cal de­vel­op­ment of on­abot­u­linum­tox­i­nA for neu­ro­genic de­tru­sor over­ac­tiv­i­ty and over­ac­tive blad­der there; gen­er­al coun­sel Bryan Smith was chief coun­sel a num­ber of busi­ness units in­clud­ing urol­o­gy; and Nori Eber­sole, now Urovant’s SVP and chief hu­man re­sources of­fi­cer, was re­spon­si­ble for sev­er­al com­mer­cial and R&D ex­pan­sions at the Botox mak­er. Katkin al­so wooed Michael Mc­Fad­den from Avanir to be chief com­mer­cial of­fi­cer, and Chris­tine Ocam­po from Novus Ther­a­peu­tics to be chief ac­count­ing of­fi­cer. High pro­file ex­ec teams are a hall­mark of Roivant sub­sidiaries, as are as­sets from Big Phar­ma — Urovant’s lead drug for over­ac­tive blad­der, vide­gron, was in-li­censed from Mer­ck.

→ As Third Rock start­up Rev­o­lu­tion Med­i­cines opens a new chap­ter in its his­to­ry with a $56 mil­lion ven­ture round aimed at mov­ing its first ex­per­i­men­tal ther­a­py in­to the clin­ic, it has al­so been re­cruit­ing new ex­ecs for the top team. Ryan Mar­tins joined as chief fi­nan­cial of­fi­cer, sug­gest­ing some added at­ten­tion for cap­i­tal for­ma­tion that will like­ly in­clude fresh strate­giz­ing that could lead to an IPO. Xi­aolin Wang jumped in as se­nior vice pres­i­dent, clin­i­cal de­vel­op­ment and Hird­esh Up­pal joined as vice pres­i­dent, de­vel­op­ment sci­ences. Thi­lo Schroed­er, a part­ner at can­cer spe­cial­ist Nex­tech In­vest, and Bar­bara We­ber, chief ex­ec­u­tive of­fi­cer of Tan­go Ther­a­peu­tics, joined the com­pa­ny’s board of di­rec­tors.

Sanofi has lost its glob­al di­a­betes R&D chief and re­gion­al CSO Philip Just Larsen to Ger­man phar­ma gi­ant Grü­nen­thal, leav­ing the com­pa­ny in a lurch to fill his shoes at the com­pa­ny’s Frank­furt of­fice. At Grü­nen­thal, Larsen will serve as chief sci­en­tif­ic of­fi­cer, where he will get to flex his neu­ro back­ground. “As an MD PhD with clin­i­cal neu­rol­o­gy ex­per­tise, I have first-hand ex­pe­ri­ence in pain man­age­ment, the core com­pe­tence at Grü­nen­thal,” Larsen said in a state­ment. “I am thrilled to con­tribute to the de­vel­op­ment of in­no­v­a­tive med­i­cines for high un­met med­ical needs in pain.” Be­fore join­ing Grü­nen­thal, Larsen spent six years at Sanofi — first as SVP and glob­al head of its di­a­betes di­vi­sion, and lat­er as CSO of the Ger­man hub in ad­di­tion to his for­mer role. By ex­it­ing Sanofi for the Ger­man drug­mak­er, Larsen gets to helm an ac­tive R&D group. Grü­nen­thal plans to in­tro­duce four or five new prod­ucts by 2022 with hopes of be­com­ing a $2 bil­lion busi­ness. Larsen will like­ly stay busy as the com­pa­ny dumps more in­vest­ment in R&D — along with buy­ing up spe­cial­ty drug pro­grams.

Alder Bio­phar­ma­ceu­ti­cals $AL­DR is piec­ing to­geth­er its in­ter­im team in the lead-up to an NDA for their CGRP mi­graine drug eptinezum­ab. Er­ic Carter, a biotech vet who’s been con­sult­ing for the com­pa­ny, is step­ping in as in­ter­im CMO. He’ll be re­port­ing to in­ter­im CEO Paul Cleve­land, who took the top spot fol­low­ing the abrupt de­par­ture a few weeks ago of CEO Randy Schatz­man, who found­ed the com­pa­ny. Alder is wide­ly viewed as a big step be­hind the lead­ers in this field, with Am­gen/No­var­tis in the lead.

→ Fresh off a job han­dling ear­ly-stage clin­i­cal pro­grams at In­fin­i­ty Phar­ma, Clau­dio Dan­sky Ull­mann has signed on to ad­vance Max­Cyte’s very first au­tol­o­gous CAR drug can­di­dates. The cell en­gi­neer­ing ser­vice provider was in des­per­ate need for an ex­pert to spear­head its jump in­to drug de­vel­op­ment, and Dan­sky Ull­mann, a for­mer clin­i­cal in­ves­ti­ga­tor who got his in­dus­try start at Take­da, fits the bill. He will over­see the en­try of Max­Cyte’s lead drug, MCY-M11, in­to the clin­ic.

Janssen vet An­ish Suri has land­ed his first biotech job as CSO of Cue Bio­phar­ma $CUE. The im­munol­o­gy ex­pert will chan­nel his sci­en­tif­ic ex­per­tise to guide dis­cov­ery, pre­clin­i­cal and trans­la­tion­al re­search ef­forts at the Cam­bridge, MA-based com­pa­ny, which har­ness­es im­munother­a­py for can­cer and au­toim­mune dis­eases. An­oth­er part of his job is to build new teams to work on ap­pli­ca­tions of Cue’s pre­cise im­mune mod­u­la­tion tech­nolo­gies.

→ Al­most a year af­ter launch­ing out of X-Chem, X-Bi­otix Ther­a­peu­tics has brought in a key ex­ec, two board di­rec­tors and $7 mil­lion in Se­ries A fund­ing. As chief sci­en­tif­ic of­fi­cer, Do­minic Ryan — a for­mer dis­cov­ery di­rec­tor at Cu­bist Phar­ma — will steer the biotech’s re­search strat­e­gy as it pur­sues an­tibi­ot­ic scaf­folds for mul­ti-drug re­sis­tant Gram-neg­a­tive pathogens. Waltham, MA-based X-Bi­otix is build­ing a pipeline based up­on X-Chem’s DNA en­cod­ing tech­nol­o­gy and a col­lab­o­ra­tion with sev­er­al mi­cro­bi­ol­o­gy spe­cial­ists at Har­vard. Al­so join­ing the com­pa­ny are Aduro Biotech CEO Stephen Isaacs and pri­vate eq­ui­ty part­ner Christo­pher Ray, ap­point­ed to help grow the ear­ly-stage com­pa­ny.

Gary Chris­tian­son is the new COO at Nohla Ther­a­peu­tics, with a man­date to build a com­mer­cial-ready op­er­a­tion for its pipeline of off-the-shelf cell ther­a­pies. Most re­cent­ly, Chris­tian­son worked at Cas­ca­di­an Ther­a­peu­tics, where he had the same ti­tle be­fore it got ac­quired by Seat­tle Ge­net­ics. At Nohla, Chris­tian­son will once again deal with im­munother­a­pies for au­toim­mune dis­eases — some­thing he spent plen­ty of time with at Corixa.

→ Fol­low­ing a four-year run at an ad­vi­so­ry firm, Josh Hamer­mesh is back scout­ing deals for Gami­da Cell’s epi­ge­net­ic reg­u­la­tion tech­nolo­gies. As CBO, Hamer­mesh will lead the busi­ness op­er­a­tions and cor­po­rate de­vel­op­ment strate­gies at the Is­raeli biotech’s Cam­bridge, MA of­fice. The new job adds to a slate of BD roles on his re­sume, span­ning Gen­zyme, Per­va­sis Ther­a­peu­tics and In­fin­i­ty Phar­ma. He will be joined at Gami­da Cell by Paul Nee, a for­mer Sunovion Phar­ma staffer who will take charge of mar­ket re­search, an­a­lyt­ics and com­mer­cial strate­gies as VP of mar­ket­ing.

→ Crav­ing a piece of the ac­tion, in­vestor Joep Mui­jr­ers has joined PureTech Health as CFO. Giv­en that his pri­or in­vest­ments in­clud­ed Kite Phar­ma, Abl­ynx and Juno Ther­a­peu­tics, it’s not hard to imag­ine where he’s com­ing from. At the Boston-based com­pa­ny, Mui­jr­ers will have broad au­thor­i­ty over all as­pects of its fi­nances, in­clud­ing cap­i­tal mar­kets strat­e­gy and ex­e­cu­tion, dri­ving growth for its af­fil­i­ates, strate­gic and fi­nan­cial plan­ning, and fi­nan­cial re­port­ing.

→ In a recog­ni­tion of his con­tri­bu­tions, Aaron Berg has been pro­mot­ed to chief com­mer­cial of­fi­cer at Amarin $AM­RN, re­plac­ing Mark Saly­er, who left af­ter less than a year in the job. Build­ing up­on his du­ties as VP of mar­ket­ing and sales, it is now his job to en­sure com­mer­cial growth for Vas­cepa, the triglyc­eride-low­er­ing drug cur­rent­ly in a land­mark car­dio­vas­cu­lar tri­al with re­sults an­tic­i­pat­ed in Q3.

Gos­samer Bio is wel­com­ing for­mer Leerink di­rec­tor and in­vest­ment banker Bryan Gi­rau­do to the oth­er side of the ta­ble. Gi­rau­do will lead all fi­nance and ad­min­is­tra­tive func­tions for the biotech, found­ed by ex-Re­cep­tos ex­ecs. With the $100 mil­lion round it got in Jan­u­ary and a built-in deal-heavy mod­el, the new CFO will like­ly stay busy.

→ Now that Sel­l­as has gained its foothold in the pub­lic mar­ket, Alek­sey Krylov, the in­ter­im CFO over­see­ing its re­verse merg­er with Gale­na, is giv­ing way to a per­ma­nent suc­ces­sor. Gene Mack brings a com­bi­na­tion of fi­nance con­sult­ing, biotech ex­pe­ri­ence and eq­ui­ty re­search to his new job. His re­sume al­so boasts of a num­ber of M&A and prod­uct li­cens­ing trans­ac­tions, some­thing that Sel­l­as — which is look­ing for part­ners on a can­cer vac­cine with a mixed record while prep­ping an­oth­er piv­otal Phase III can­cer study — could re­al­ly use.

→ In a boost to its cus­tomer-fac­ing units, Parex­el has re­cruit­ed Pey­ton How­ell from drug dis­trib­u­tor Amerisource­Ber­gen to be­come its chief com­mer­cial strat­e­gy of­fi­cer. Glob­al sales, cus­tomer ser­vice and sales op­er­a­tions will all be un­der her purview as How­ell takes her first crack at the bio­phar­ma ser­vice in­dus­try. She will work with CEO Jamie Mac­don­ald, who him­self joined the com­pa­ny just weeks ago.

→ East Ly­me, CT-based CRO Ph­e­si has named Paul Chew its chief med­ical of­fi­cer. A car­di­ol­o­gist by train­ing, Chew cut his teeth at Bris­tol-My­ers Squibb be­fore as­sum­ing a slate of clin­i­cal roles at Sanofi. His most re­cent gig at dig­i­tal ther­a­peu­tics start­up Oma­da Health makes for a nat­ur­al tran­si­tion to Ph­e­si, which likes to tout its clin­i­cal tri­als data­base and pre­dic­tive an­a­lyt­ics tools.

→ An­tic­i­pat­ing a com­mer­cial launch for its an­ti-in­fec­tive drug, Den­mark’s Xel­lia Phar­ma has ap­point­ed Craig Boyd to the pres­i­dent seat of its US busi­ness. His hir­ing co­in­cides with a plan to open a new of­fice in Chica­go, pro­vid­ing an an­chor for the man­u­fac­tur­ing fa­cil­i­ties in Cleve­land that’s sched­uled to come in­to full op­er­a­tion this year. A for­mer No­var­tis sales ex­ec­u­tive, Boyd jumps from con­tract re­search or­ga­ni­za­tion En­vi­go. That ex­pe­ri­ence might come in­to play as he seeks part­ner­ships and in­creas­es Xel­lia’s man­u­fac­tur­ing foot­print in the US.

→ Af­ter get­ting a sev­en-year in­tro­duc­tion to bio­phar­ma at con­tract re­search and man­u­fac­tur­ing or­ga­ni­za­tion AM­RI, Lori Hen­der­son is now Mod­er­na’s gen­er­al coun­sel and cor­po­rate sec­re­tary. Her new col­leagues like her blend of reg­u­la­to­ry, gov­er­nance and cor­po­rate de­vel­op­ment ex­pe­ri­ence, sug­gest­ing that she will play a sim­i­lar role in com­pa­ny growth and part­ner­ships at the biotech uni­corn ad­vances its mes­sen­ger RNA ther­a­peu­tics.

Re­cro Gainesville, a CD­MO based out of Geor­gia, has hired Heather Sug­rue to lead its busi­ness de­vel­op­ment team, con­vinced by a track record she’s es­tab­lished at Pan­theon, Ricer­ca Bio­sciences and MDS Phar­ma Ser­vices.

Te­va vet Mau­reen Ca­vanaugh has been named se­nior vice pres­i­dent and chief com­mer­cial op­er­a­tions of­fi­cer at gener­ic drug man­u­fac­tur­er Lan­nett, trig­ger­ing a shuf­fle in the C-suite. COO John Ko­zlows­ki will now be­come chief of staff and strat­e­gy of­fi­cer, while John Abt, VP of qual­i­ty and an old col­league of Ca­vanaugh’s, is pro­mot­ed to chief qual­i­ty and op­er­a­tions of­fi­cer.

→ In a bid to strength­en its Alder­ley Park site, Con­cept Life Sci­ences has ap­point­ed Mer­ck vet Matil­da Bing­ham as site di­rec­tor and David Hig­ton as prin­ci­pal sci­en­tist, with a fo­cus on bioin­for­mat­ics. Both were re­cent­ly at UK bio­phar­ma com­pa­nies — Bing­ham at Redx Phar­ma and Hig­ton at Cypro­tex.

Qual­i­ty Con­trol in Cell and Gene Ther­a­py – What’s Re­al­ly at Stake?

In early 2021, Bluebird Bio was forced to suspend clinical trials of its gene therapy for sickle cell disease after two patients in the trial developed cancer. As company scientists rushed to assess whether there was any causal link between the therapy and the cancer cases, Bluebird’s stock value plummeted – as did those of multiple other biopharma companies developing similar therapies.

While investigations concluded that the gene therapy was unlikely to have caused cancer, investors and the public may be more skittish regarding the safety of gene and cell therapies after this episode. This recent example highlights how delicate the fields of cell and gene therapy remain today, even as they show great promise.

Law pro­fes­sors call for FDA to dis­close all safe­ty and ef­fi­ca­cy da­ta for drugs

Back in early 2018 when Scott Gottlieb led the FDA, there was a moment when the agency seemed poised to release redacted complete response letters and other previously undisclosed data. But that initiative never gained steam.

Now, a growing chorus of researchers are finding that a dearth of public data on clinical trials and pharmaceuticals means industry and the FDA cannot be held accountable, two law professors from Yale and New York University write in an article published Wednesday in the California Law Review.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Novavax CEO Stanley Erck at the White House in 2020 (Andrew Harnik, AP Images)

As fears mount over J&J and As­traZeneca, No­vavax en­ters a shaky spot­light

As concerns rise around the J&J and AstraZeneca vaccines, global attention is increasingly turning to the little, 33-year-old, productless, bankruptcy-flirting biotech that could: Novavax.

In the now 16-month race to develop and deploy Covid-19 vaccines, Novavax has at times seemed like the pandemic’s most unsuspecting frontrunner and at times like an overhyped also-ran. Although they started the pandemic with only enough cash to last 6 months, they leveraged old connections and believers into $2 billion and emerged last summer with data experts said surpassed Pfizer and Moderna. They unveiled plans to quickly scale to 2 billion doses. Then they couldn’t even make enough material to run their US trial and watched four other companies beat them to the finish line.

FDA of­fers scathing re­view of Emer­gent plan­t's san­i­tary con­di­tions, em­ploy­ee train­ing af­ter halt­ing pro­duc­tion

The FDA wrapped up its inspection of Emergent’s troubled vaccine manufacturing plant in Baltimore on Tuesday, after halting production there on Monday. By Wednesday morning, the agency already released a series of scathing observations on the cross contamination, sanitary issues and lack of staff training that caused the contract manufacturer to dispose of millions of AstraZeneca and J&J vaccine doses.

Brad Bolzon (Versant)

Ver­sant pulls the wraps off of near­ly $1B in 3 new funds out to build the next fleet of biotech star­tups. And this new gen­er­a­tion is built for speed

Brad Bolzon has an apology to offer by way of introducing a set of 3 new funds that together pack a $950 million wallop in new biotech creation and growth.

“I want to apologize,” says the Versant chairman and managing partner, laughing a little in the intro, “that we don’t have anything fancy or flashy to tell you about our new fund. Same team, around the same amount of capital, same investment strategy. If it ain’t broke, don’t fix it.”

But then there’s the flip side, where everything has changed. Or at least speeded into a relative blur. Here’s Bolzon:

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Sen. Patty Murray (D-WA) (Graeme Sloan/Sipa USA/Sipa via AP Images)

Sen­a­tors to NIH: Do more to pro­tect US bio­med­ical re­search from for­eign in­flu­ence

Although Thursday’s Senate health committee hearing was focused on how foreign countries and adversaries might be trying to steal or negatively influence biomedical research in the US, the only country mentioned by the senators and expert witnesses was China.

Committee chair Patty Murray (D-WA) made clear in her opening remarks that the US cannot “let the few instances of bad actors” overshadow the hard work of the many immigrant researchers in the US, many of which have won Nobel prizes for their work. But she also said, “There is more the NIH can be doing here.”

Jenny Rooke (Genoa Ventures)

Ear­ly Zymer­gen in­vestor Jen­ny Rooke re­flects on 'chimeras' in biotech, what it takes to spot a $500M gem

When Jenny Rooke first heard of Zymergen back in 2014, she knew she was looking at something different and exciting. The Emeryville, CA biotech held the promise of blending biology and technology to solve a huge unmet need for cost-effective chemicals — of all things — and a stellar founding team to boot.

But back then, West Coast venture capitalists didn’t see in Zymergen the one thing they were looking for in a winning biotech: therapeutic potential. Rooke, however, saw an opportunity and made her bets. Seven years later, that bet is paying off in a big way.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 107,500+ biopharma pros reading Endpoints daily — and it's free.

Saurabh Saha at Endpoints News' #BIO19

On the heels of $250M launch, Centes­sa barges ahead with an IPO to fu­el its 10-in-1 Medicxi pipeline

Francesco De Rubertis made no secret of IPO plans for Centessa, his 10-in-1 legacy play. Barely two months later, the S-1 is in.

The hot-off-the-press filing depicts the same grand vision that the longtime VC touted when he did the rounds in February: Take the asset-centric mindset that he’s been preaching at Medicxi over the years, and roll up a bunch of biotech upstarts, with unrelated risk profiles, into 1 pharma company that can carry on the development at scale.

Emma Walmsley, GlaxoSmithKline CEO (Kevin Dietsch/Pool via CNP/Alamy)

Glax­o­SmithK­line hus­tles the 7th PD-1 past the fin­ish line with Jem­per­li. But how big will up­take be?

Everything came up sevens for GlaxoSmithKline on Thursday as the pharma notched the seventh PD-1 approval seven years after the first such drugs were OK’ed in Keytruda and Opdivo. But will it bring GSK good fortune?

The FDA granted accelerated approval to dostarlimab, to be branded Jemperli, to treat recurrent or advanced endometrial cancer in a specific subset of patients following platinum-based chemo. It’s a drug that came to GSK through its buyout of Tesaro, which it snapped up for $5.1 billion back in December 2018.